Clinical Trial Update: Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating chemotherapy with or without adebrelimab and trastuzumab deruxtecan for HR-positive, HER2-low early-stage breast cancer. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)
• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING